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Background: The role of drug-eluting balloons (DEB) is unclear. Increasing evidence has shown a benefit for the
treatment of in-stent restenosis. Its effect on de novo coronary lesions is more controversial. Several smaller
randomized trials found conflicting results.
Methods: This is a systematic review and meta-analysis of randomized controlled trials (RCT) evaluating the effect
of local Paclitaxel delivery/drug eluting balloons (DEB) (+/− bare metal stent) compared to current standard therapy
(stenting) to treat de novo coronary lesions. Data sources for RCT were identified through a literature search from
2005 through 28 December 2012. The main endpoints of interest were target lesion revascularization (TLR), major
adverse cardiac events (MACE), binary in-segment restenosis, stent thrombosis (ST), myocardial infarction (MI), late
lumen loss (LLL) and mortality. A random effects model was used to calculate the pooled relative risks (RR) with
95% confidence intervals.
Results: Eight studies (11 subgroups) and a total of 1,706 patients were included in this analysis. Follow-up
duration ranged from 6 to 12 months. Overall, DEB showed similar results to the comparator treatment. The relative
risk (RR) for MACE was 0.95 (0.64 to 1.39); P = 0.776, for mortality it was 0.79 (0.30 to 2.11), P = 0.644, for stent
thrombosis it was 1.45 (0.42 to 5.01), P = 0.560, for MI it was 1.26 (0.49 to 3.21), P = 0.629, for TLR it was 1.09 (0.71 to 1.68);
P = 0.700 and for binary in-stent restenosis it was 0.96 (0.48 to 1.93), P = 0.918. Compared to bare metal stents (BMS),
DEB showed a lower LLL (− 0.26 mm (−0.51 to 0.01)) and a trend towards a lower MACE risk (RR 0.66 (0.43 to 1.02)).
Conclusion: Overall, drug-eluting balloons (+/− bare metal stent) are not superior to current standard therapies (BMS or
drug eluting stent (DES)) in treating de novo coronary lesions. However, the performance of DEB seems to lie in between
DES and BMS with a trend towards superiority over BMS alone. Therefore, DEB may be considered in patients with
contraindications for DES. The heterogeneity between the included studies is a limitation of this meta-analysis; different
drug-eluting balloons have been used.
Keywords: Coronary artery disease, Stents, Drug-eluting balloon, Percutaneous coronary interventionBackground
Approximately 600,000 percutaneous coronary interven-
tions (PCI) are performed in the United States each year
[1]. Even though the frequency of restenosis after PCI and
need for repeat revascularization has been reduced with
the advent of drug eluting stents (DES), it still remains the
main disadvantage compared to coronary bypass surgery* Correspondence: pascalmeier74@gmail.com
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reproduction in any medium, provided the or[2]. Another Achilles heel of DES is the need for longer
term dual antiplatelet therapy of usually 12 months’
duration compared to only one month for bare metal
stents (BMS) [3,4]. Due to this limitation, there remains a
proportion of about 20 to 30% of patients where bare metal
stents are preferred [5]. Despite stent design improvement,
drug-eluting and bare-metal stents both come with a
worrying risk of stent thrombosis [6]. It would be optimal
if PCI could be performed without leaving behind a
permanent device. One option is the use of bioabsorbable
scaffolds [7]. Another alternative includes the use of drug
eluting balloons (DEB). DEB have been of proven benefitl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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randomized trials [8]. However, the use of DEB in the
setting of de novo coronary lesions has only been addressed
in a few smaller randomized trials with very limited power
for clinical endpoints [9,10]. The aim of this study was a
systematic review and meta-analysis of the effectiveness of
local drug delivery with DEB (either in conjunction with
bare-metal stenting or following plain old balloon angio-
plasty (POBA)) versus conventional treatment modalities
in de novo coronary lesions.Methods
The study was performed according to the Preferred
Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) guidelines for meta-analyses of randomized
trials (see Additional file 1) [11,12]. Planning and study
design were done by two authors (GF, PM), including
creation of an electronic database with variables of interest.
Primary and secondary endpoints, variables of interest and
search strategy (databases, sources for unpublished data)
were defined in a strategy outline which can be obtained
from the study authors on request. All studies included in
this analysis were performed with the approval of an appro-
priate ethics committee and in compliance with the
Helsinki Declaration.Search strategy
We searched EMBASE, PubMed, MEDLINE, BIOS and
ISI Web of Science from 2005 through 28 December
2012. In addition, abstract lists and conference proceed-
ings from the 2006 to 2012 scientific meetings of the
American College of Cardiology, the European Society
of Cardiology, the Symposium on Transcatheter Cardio-
vascular Therapeutics, the American Heart Association,
and the World Congress of Cardiology were searched.
We have not included studies published before 2005, as
the main priority of this review is to illustrate the
updated literature and the current effects of the different
presented techniques on specific endpoints (for example,
without significant effects of changes in clinical practice
over time. We also considered published review articles,
editorials and internet-based sources of information
(www.tctmd.com, www.theheart.org, www.europcronline.
com, www.cardiosource.com and www.crtonline.com) to
assess potential information on studies of interest.
Reference lists of selected articles were reviewed for
other potentially relevant citations. No language restriction
was applied.
The search terms used included "drug coated balloon",
"drug eluting balloon", “randomized controlled trial”.
The detailed search syntax for the database Medline is
shown in Additional file 2. The syntax for other databases
was similar but was adapted where necessary.Study selection
In a two-step selection process, the titles and abstracts
of all citations were reviewed by two researchers (PM,
GF) to identify potentially relevant studies. In a second
step, the corresponding publications were reviewed in
full text to assess if studies met the following inclusion
criteria: drug eluting balloon versus comparator treatment,
randomized controlled trial (Figure 1).
Data extraction and quality assessment
Relevant information from the articles including baseline
clinical characteristics of the study population and outcome
measures were extracted using the prepared standardized
extraction database (Microsoft EXCEL). We assessed trial
quality by evaluating randomization and allocation conceal-
ment, intention-to-treat analysis, blinded assessment of
outcome measures, premature stopping of patient enrol-
ment, and reporting on dropouts, but without using a qual-
ity score given the limitations inherent to such an approach
(Table 1) [13].
Endpoints and definitions
Baseline variables, and clinical and angiographic data
were extracted. Variables of interest were a composite of
major adverse cardiac events (MACE), target lesion
revascularization (TLR), all-cause mortality, myocardial
infarction, in-stent restenosis (≥50% diameter stenosis)
and late lumen loss (LLL, in segment). For the definition
in the individual trial, see Table 2.
CAD, coronary artery disease; DEB, drug eluting bal-
loon; DES, drug eluting stent; EPC, endothelial progenitor
cells; EPC-BMS Endothelial Progenitor Cell capturing
Bare Metal Stent; LLL, in-stent Late Lumen Loss; MACE,
definition of major adverse cardiac events; MI, myocardial
infarction; mts, months; STEMI, ST-Elevation Myocardial
Infarction; TLR, target lesion revascularization; TVR,
target vessel revascularization.
Data synthesis and analysis
Data of included studies were combined to estimate the
pooled impact (risk ratio, RR) of DEB versus a comparator
treatment. Study subgroups comparing DEB with either
DES or BMS were the unit of analysis, DES and BMS are
rather different comparators. Calculations were based on a
DerSirmonian and Laird random-effects model [14]. This
model assumes that the true effects vary between studies
for unknown reasons. The primary summary measure usu-
ally reported is the estimated average effect across studies
[15]. Continuity correction was used when no event
occurred in one group to allow calculation of a RR [16].
Heterogeneity among trials was quantified with Higgins'
and Thompson's I2 [17]. I2 can be interpreted as the per-
centage of variability due to heterogeneity between studies
rather than sampling error. An I2 >50% was considered as
Figure 1 Study selection process. DEB drug eluting balloon.
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result estimates of the average effect across studies with
95% confidence intervals in brackets. In addition, we also
calculated 95% prediction intervals as described by Higgins
et al. [15,18]. These intervals predict the effect that we
would potentially expect to see in a new study. These data
are presented in the sensitivity analysis paragraph. We did
not test for publication bias or small study effects due to
the small number of studies included in this analysis.
We performed stratified analyses for the different
comparator treatments (BMS or DES). We performed
sensitivity analyses excluding the one trial which was not
yet published in full text but only as an abstract, [19] the
trial which did use DEB alone (without BMS), [20]
excluding the trial using progenitor cell capturing stents
[21], and excluding the study using a special drug deliv-
ery catheter instead of a drug eluting balloon [22].
All analyses were performed with R, version 2.15.1
(package “meta”), R Foundation for Statistical Comput-
ing, Vienna, Austria [23].Table 1 Quality assessment of studies investigating DEB + BM
Study Control group(s) Randomization/ allocation
concealment
Inte
DEB-AMI DES, BMS 2
Stella et al. DES, BMS 2
PEPCAD III DES 1
PERFECT EPC-BMS 2
BELLO DES 2
Herdeg et al. DES, BMS 2
Ali et al. DES 2
PICCOLETTO DES 2
Scoring: 0 points = no information or insufficient. 1 = Sufficient quality. 2 = Good qResults and discussion
Description of included studies
A total of 90 articles were reviewed and 8 studies (11 sub-
groups) including 1,706 patients satisfied the predetermined
inclusion criteria (Figure 1) [9,10,19-22,24,25]. Studies using
DEB for in-stent restenosis treatment were not considered.
All studies used paclitaxel-eluting balloons or delivery
catheters. The DEB AMI trial enrolled only patients with
STEMI while all the others excluded this patient group
[10]. The eight studies presented seven subgroups where
DEB was compared with a DES and four subgroups
comparing DEB with BMS. Table 1 shows the baseline
characteristics of the included studies.Major adverse cardiac events MACE
The definition of MACE differed slightly among the
trials (Table 1). Overall, DEB were not superior to the
control group (stenting with DES or BMS) (RR 0.95
(0.64 to 1.39); P = 0.776) (Figure 2).S vs control groups
ntion to treat
analysis
Blinded endpoint
assessment
Premature
stopping
Reporting of
dropouts
2 2 2 2
2 2 1 2
2 0 1 1
2 1 1 1
2 1 1 2
2 1 2 2
1 1 1 1
2 1 2 2
uality.
Table 2 Baseline characteristics of included trials
Study Paclitaxel eluting
balloon
Controls
stent type(s)
Setting Clopidogrel (mts) Follow-up
(mts)
Primary
endpoint
MACE TLR Bare metal
stenting
DEB-AMI DIOR 2nd generation TAXUS DES, Genius
Magic Euroscore BMS
STEMI 12 6 LLL death, MI, TVR restenosis
>50% ischemia
100%
Stella et al. DIOR 1st generation TAXUS DES,
Liberté BMS
stable/unstable
CAD, bifurcation
3 after BMS,
12 after DES
12 (angio 6) LLL death, MI, TVR restenosis
>50% ischemia
100%
PEPCAD III Coroflex DEBlue Cypher DES stable/unstable CAD 1 after DEB 9 LLL NA NA 100%
PERFECT SeQuent Please+
PERFECT Stent
PERFECT Stent
(EPC capturing Stent)
Stable CAD 3 6 LLL death, MI, TLR NA 100%
BELLO IN.PACT Falcon TAXUS DES stable/unstable
CAD small vessels
3 after DEB,
12 after DES
6 LLL death, MI, TVR any repeat
revascularization
20.2%
Herdeg et al. GENIE Acrostak TAXUS DES,
Multi-Link BMS
stable CAD 6 6 LLL death, MI, TVR,
stent thrombosis
any repeat
revascularization
100%
Ali et al. SeQuent Please TAXUS DES stable CAD in diabetics NA 9 LLL NA NA 100%
PICCOLETTO DIOR 1st generation TAXUS DES stable/unstable
CAD small vessels
1 after DEB, 3 after BMS,
12 after DES/unstable
9 (angio 6) diameter
stenosis
death, STEMI, TLR >50% restenosis NA (>100%)
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The need for target lesion revascularization (TLR) was
not significantly different between DEB and the control
group (1.09 (0.71 to 1.68); P = 0.700). (Figure 3) In most
studies, TLR was clinically driven (Table 1).
Binary in-segment restenosis
The rate of in-segment restenosis was similar between DEB
and the control group (0.96 (0.48 to 1.93), P = 0.918)
(Figure 4).
Late luminal loss
The LLL was similar for DEB and the control group
(mean difference - -0.02 mm (−0.23 to 0.18); P = 0.818)
(Figure 5).
All-cause mortality
The mortality was not significantly different for DEB
and the control group (0.79 (0.30 to 2.11), P = 0.644)
(Figure 6).
Myocardial infarction
Overall, the risk for myocardial infarction was not signifi-
cantly different between DEB and the control group (RR
1.26 (0.49 to 3.21), P = 0.629) (Figure 7).
Stent thrombosis
Overall, stent thrombosis (ST) was a very rare event and
not significantly different between DEB and the control
group (RR 1.45 (0.42 to 5.01), P = 0.560) (Figure 8).
Sensitivity analyses
We also calculated the prediction intervals for those
clinical endpoints that were statistically significant. TheseFigure 2 Forest plot of risk ratios (RR) for major adverse cardiac even
adverse cardiac events; RR, risk ratio. Markers represent point estimates of r
meta-analysis. Horizontal bars indicate 95% confidence intervals.intervals predict the effect that we would potentially
expect to see in a future study. The prediction intervals all
crossed the line of unity and were, therefore, not signifi-
cant. The influence analyses, omitting one trial at a time,
showed rather robust results that were not relevantly
influenced by a single trial (Table 3).
Subset analyses
We have also analyzed the data for the subset of trials
which compared DEB with drug eluting stents or with
bare metal stents.
MACE
Compared to BMS, there was a trend towards a lower
MACE risk for DEB (RR 0.66 (0.43 to 1.02), P = 0.060).
Compared to DES, there was no significant difference
(RR 1.23 (0.72 to 2.11), P = 0.750).
TLR
Compared to BMS, the TLR for DEB was not significantly
different (RR 0.71 (0.46 to 1.10), P = 0.120). Compared to
DES, the RR was 1.53 (0.90 to 2.56); P = 0.117.
Binary restenosis
Compared to BMS, the RR was 0.51 (0.18 to 1.44), P =
0.203. Compared to DES, the RR was 1.61 (0.67 to 3.85),
P = 0.286.
Late lumen loss
Compared to BMS, LLL was lower for DEB (− 0.26 mm
(−0.51 to −0.01); P = 0.040). Compared to DES, LLL was
not significantly different (0.15 mm (−0.06 to 0.36);
P = 0.162).ts. CI, confidence interval; DEB, drug eluting balloon; MACE, major
isk ratios, marker size represents study weight in random-effects
Figure 3 Forest plot of risk ratios (RR) for target lesion revascularization. CI, confidence interval; DEB, drug eluting balloon; RR, risk ratio;
TLR, target lesion revascularization.
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Compared to BMS, the RR for DEB was 0.29 (0.06 to
1.48), P = 0.137.
Compared to DES the RR was 1.42 (0.41 to 4.85),
P = 0.579.
Myocardial infarction
Compared to BMS, the RR was 1.09 (0.33 to 3.62);
P = 0.893.
Compared to DES, the RR was 1.45 (0.35 to 6.06);
P = 0.613.
Stent thrombosis
When compared to BMS the RR was 1.75 (0.29 to 10.60),
P = 0.545, compared to DES it was 1.22 (0.22 to 6.76),
P = 0.819.
We have also analyzed the data of the two trials which
did compare DEB alone (and only provisional stenting with
a bare metal stent) versus DES (BELLO+PICOLETTO).
For MACE the RR was 1.21 (0.30 to 4.94); P = 0.793. For
mortality it was 1.03 (0.148 to 7.14); P = 0.977. For
MI the RR was 0.61 (0.05 to 8.41); P = 0.715. The
RR for TLR was 1.35 (0.26 to 6.92); P = 0.722 and
for binary re-stenosis the RR was 1.36 (0.31 to 6.06);
P = 0.686.
Discussion
This is the first meta-analysis assessing the clinical
effectiveness of drug-eluting balloons to treat de novo
coronary lesions. Overall, DEB were not superior to
current standard therapy using DES or BMS. How-
ever, the present study shows signals suggesting thatthe use of DEB may be superior to BMS alone
although larger trials are needed for confirmation.
DEB may be beneficial in patients who are not
eligible for DES implantation or in small vessel
disease, where stenting is undesirable or not possible.
DEB are an established treatment for in-stent
restenosis and recommended by current European
guidelines (class IIa, level of evidence B) [26]. The
role of DEB for percutaneous coronary intervention
(PCI) of de novo coronary lesions has not been well
defined yet. Currently, neither the European nor
American guidelines recommend DEB for de novo
lesions.
Potential benefits of DEB for treatment of de novo
coronary lesions
DES implantation is the gold standard for percutaneous
treatment of de novo lesions in major coronary vessels
[26]. However, there are several pitfalls related to
DES use where DEBcould find its niche as a potent
DES alternative:
1) After DES implantation, dual antiplatelet therapy is
mandatory for 6 to 12 months [26]. Therefore, patients
who are at an increased bleeding risk or who are
awaiting urgent surgery will mainly receive BMS,
where dual antiplatelet therapy is required for one
month only. Notably, implantation of BMS is
associated with an elevated risk for in-stent restenosis
(ISR) of 20 to 30% compared to 10 to 15% with DES
after one year [26,27]. In diabetics, representing a high
risk population, the relative risk for ISR is further
Figure 4 Forest plot of risk ratios (RR) for restenosis (≥50% diameter-stenosis). CI, confidence interval; DEB, drug eluting balloon; RR, risk ratio.
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via a DEB and consecutive implantation of a BMS
might result in both, a reduced rate of ISR and a
significantly reduced duration of dual anti-platelet
therapy if compared to DES. In particular, clopidogrel
is recommended for one to three months after DEB-
PTCA (percutaneous transluminal coronary
angioplasty), at least in the setting of PCI for stable
CAD [19,24]. In the setting of small vessel disease,
where the results of balloon angioplasty appear
non-inferior to those after stenting, the use of DEB
only might be a reasonable option [29].
2) An appropriate technique of drug delivery to prevent
ISR is crucial for a favorable long-term outcome [30,31].
Not only the optimal stent/balloon design (for example,
design and diameter of the stent struts), but also the
properties of the ideal carrier matrix are hotly debatedFigure 5 Forest plot of risk ratios (RR) for late lumen loss. CI, confidence[32]. Among different DES platforms, several authors
have been able to demonstrate an association of (late)
stent thrombosis with the polymer and ISR due to a
delayed healing and endothelialization process [33,34].
More recently, bioabsorbable polymers that leave, in
effect, a BMS after drug delivery have been developed
with promising results [35]. Even polymer-free DES,
with less reliable drug-release-kinetics, have been
proposed to overcome the burden of depleted
permanent polymers [36]. However, all of these
proposed DES types require antiplatelet therapy for at
least six months [27].
3) DEB deliver higher paclitaxel doses (300 to 600 ug with
DEB vs. 100 to 200 ug with DES), and as the drug
eluting stent struts commonly cover only 20% of the
injured vessel wall, the larger DEB surface area
guarantees more uniform drug delivery [37].interval; DEB, drug eluting balloon; SD, standard deviation.
Figure 6 Forest plot of risk ratios (RR) for mortality. CI, confidence interval; DEB, drug eluting balloon; SD, standard deviation.
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lesions
In the present study, we investigated eight randomized
controlled trials, involving 1,706 patients, who under-
went DEB and bare metal stenting versus implantation
of conventional BMS or DES for de novo coronary le-
sions. Overall, there were no significant differences be-
tween the DEB and the control groups in terms of
mortality or MACE.
In particular, there appears to be a trend towards a bene-
ficial effect of DEB if compared to BMS alone. Contrarily,
DEB tended to be inferior compared to DES. Therefore,
patients who are eligible for a DES should currently not beFigure 7 Forest plot of risk ratios (RR) for myocardial infarction. CI, co
SD, standard deviation.treated with a DEB. However, DEB might be considered as
a valid option for patients who are at high risk for in-stent
restenosis and those who cannot receive a DES.
The possible reasons for the inferior performance of
DEB in comparison to DES remain speculative, especially
as all balloons and the vast majority of DES in the analysis
were covered with paclitaxel. Balloons were covered with
(1-)3 ug/m2 paclitaxel [37], whereas the predominantly
used DES, TAXUS Liberte slow release stent, incorporates
1 ug/mm2. As outlined above, not only stent design and
the anti-proliferative drug, but also the release kinetics
from the balloon/stent surface into the vessel wall are
crucial. Indeed, the drug release kinetics of DEB are verynfidence interval; DEB, drug eluting balloon; MI, myocardial infarction;
Figure 8 Forest plot of risk ratios (RR) for stent thrombosis. CI, confidence interval; DEB, drug eluting balloon; SD, standard deviation; ST,
stent thrombosis.
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Following POBA with a standard balloon, DEB are inflated
for 30 to 120 seconds, in accordance with the manufac-
turers’ recommendations. Despite this relatively short con-
tact time between balloon and vessel wall and the rapid
decay of paclitaxel blood concentration, paclitaxel pene-
trates the vessel wall easily due to its highly lipophilic prop-
erties. Furthermore, the biologic effects of paclitaxel last for
several days and although in some DEB there is an excipi-
ent to facilitate drug transfer there is no permanent poly-
mer involved ([37]). In contrast, the TAXUS Liberté stent
releases paclitaxel very slowly and the carrier polymer is
permanently attached to the stent platform [37].
In several long-term, follow-up trials the TAXUS stent
was associated with an increased risk of late stent
thrombosis, occurring sometimes even more than two
years after the index intervention [27]. A potential im-
pact of DEB use on the rate of late stent thrombosis
might have been undetected in the present meta-analysisTable 3 Sensitivity analyses
Endpoint Confidence
intervals
Prediction
intervals
Only published
data
Wit
STE
MACE 0.95 (0.64 to 1.39) 0.95 (0.35 to 2.52) 0.95 (0.64 to 1.39) 0.84
TLR 1.09 (0.71 to 1.68) 1.09 (0.31 to 3.83) 0.97 (0.63 to 1.50) 1.01
Binary
restenosis
0.96 (0.48 to 1.93) 0.96 (0.10 to 9.05) 0.96 (0.48 to 1.93) 0.77
MI 1.26 (0.49 to 3.21) 1.26 (0.13 to 11.83) 0.86 (0.40 to 1.85) 1.13
Mortality 0.79 (0.30 to 2.11) NA 0.58 (0.20 to 1.71) 0.78
ST 1.45 (0.42 to 5.01) NA 1.45 (0.42 to 5.01) 1.13
BMS, bare metal stent; DEB, drug eluting balloon; MACE, major adverse cardiac eve
ST, stent thrombosis; TLR, target lesion revascularization.as the average follow-up period of eight months was
relatively short. Of note, the reported number of in-stent
thromboses was very low in all studies.
It has to be considered that different types of drug-
eluting balloons have been used among trials included in
this meta-analysis (Table 2) The PICCOLETO trial, for
example, used the first generation Dior balloon. This bal-
loon has been iterated and used a new carrier (Shellac®)
which demonstrated an about 20-fold increased paclitaxel
concentration in the tissue [38]. This progress in DEB
technology may lead to improved results in future trials.
Limitations
This meta-analysis is only based on relatively small and very
heterogeneous randomized controlled trials. Although the
formal testing did not reveal a major inter-study heterogen-
eity, there are major differences between the study designs.
The main comparators were the DES or BMS. These stent
platforms perform rather differently and we, therefore,hout
MI
Only combined
DEB+BMS
Excluding
progenitor
cell stent
DEB exclusively
(0.61 to 1.15) 0.84 (0.61 to 1.15) 0.95 (0.64 to 1.39) 1.07 (0.67 to 1.70)
(0.68 to 1.51) 1.00 (0.65 to 1.55) 1.20 (0.79 to 1.82) 1.18 (0.70 to 1.99)
(0.40 to 1.48) 0.82 (0.40 to 1.66) 1.18 (0.59 to 2.35) 1.20 (0.48 to 2.96)
(0.42 to 3.06) 1.18 (0.43 to 3.24) 1.30 (0.46 to 3.65) 1.69 (0.62 to 4.59)
(0.29 to 2.15) 0.76 (0.27 to 2.18) 0.88 (0.31 to 2.45) 0.93 (0.32 to 2.71)
(0.29 to 4.40) 1.50 (0.41 to 5.57) 1.52 (0.41 to 5.63) 1.59 (0.40 to 6.36)
nts; MI, myocardial infarction; RR, relative risk (and 95% confidence intervals);
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(DES or BMS) and study subgroups as our unit of analysis.
However, even the pooled analysis of the eight trials has a
limited statistical power when stratifying the analysis based
upon the stent type. This is especially the case for rare
events such as stent thrombosis and death. These results
have to be interpreted with caution. Apart from two studies
(which used sirolimus [19] and an EPC capturing stent [22]
respectively), paclitaxel eluting stents served as the DES
control group in the investigated trials. Newer generation
DES might, therefore, even outperform the results of the
paclitaxel eluting stent in the present study.
Hard endpoint outcomes (myocardial infarction, definite
or probable stent thrombosis and death) need to be
interpreted with care since the meta-analysis might be too
small to detect statistical differences in such rare events.
Nevertheless, we find it reassuring that there appear to be
no significant differences between DEB and BMS or DES
from a safety standpoint.Outlook
Currently, paclitaxel is the only available anti-proliferative
drug that is mounted onto the DEB. Different alternatives,
like zotarolimus, sirolimus or everolimus, which have
already been used successfully on different DES platforms,
might also translate into improved outcomes when used for
DEB [39]. Indeed, a zotarolimus eluting balloon has already
been tested in a swine model [40]. The first DEB
study is currently recruiting patients with stable CAD
and will compare DEB/BMS vs. a zotarolimus eluting
balloon (NCT01539603). Further studies are recruiting pa-
tients with STEMI (DEB/BMS vs. TAXUS NCT00856765)
or NSTEMI (PEPCAD NSTEMI NCT01489449). The
BASKET-SMALL2 trial will investigate the cost-
effectiveness of DEB vs. TAXUS in small vessels
(NCT01574534). Many more prospective randomized
trials are currently recruiting patients to investigate
the optimal use of DEB in de novo coronary lesions.Conclusion
Overall, the results of drug-eluting balloons (in combin-
ation with BMS or as stand-alone therapy) appear compar-
able to BMS and paclitaxel eluting stents for de novo
coronary artery lesions. Compared to BMS exclusively,
there are signals for a potential benefit of DEB, but larger
trials would be needed to detect a significant difference.
DEB may be beneficial in cases where bare metal stenting is
considered as the only choice and patients are at high risk
for ISR (for example, diabetics), to reduce the need for long
term dual antiplatelet therapy and following POBA in small
vessels. The heterogeneity between the included studies is a
limitation of this meta-analysis; different drug-eluting
balloons have been used.Additional files
Additional file 1: PRISMA 2009 Checklist.
Additional file 2: Search strategy for MEDLINE (search date 13
December 2012).
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